Skip to main content

Table 5 Literature on submandibular gland-sparing IMRT for oropharynx cancer

From: Submandibular gland-sparing radiation therapy for locally advanced oropharyngeal squamous cell carcinoma: patterns of failure and xerostomia outcomes

Study N Definitive RT Mean cSMG dose (Gy) Disease outcome Late xerostomia
Univ. of Washington (present report) 76 86% 30.7 No peri-SMG recurrence 23% grade 2+ at 6 months No permanent grade 3 + 
Helsinki Univ., Finland [24] 50 49%* 27.8 No peri-SMG recurrence No permanent grade 3+
VU Univ. Med. Ctr., The Netherlands [30] 20 100% 34.1 No peri-SMG nodal recurrence Not reported
Univ. of Michigan [13] 17† 100% ~43 No contralateral level I recurrence No grade 3+
Centre Eugene Marquis, France [31] 8 100% 33.8 No peri-SMG recurrence No grade 3+
  1. *Number is from larger series including other disease sites.
  2. †Patients with contralateral SMG dose <50 Gy were extracted from a larger group of 78 patients (personal communication with Avraham Eisbruch). Of larger group, 92% had oropharynx cancer.